Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:BVSNASDAQ:PPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBVSBioventus$6.82-2.8%$6.72$5.73▼$14.38$560.22M0.84431,357 shs428,692 shsPPHVanEck Pharmaceutical ETF$87.80-0.3%$87.69$77.67▼$99.51$609.33M0.72279,163 shs221,162 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBVSBioventus0.00%+5.52%+6.79%-13.62%+22.54%PPHVanEck Pharmaceutical ETF0.00%+0.67%-1.39%+6.95%-3.68%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBVSBioventus2.7063 of 5 stars3.30.00.00.00.04.21.3PPHVanEck Pharmaceutical ETFN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBVSBioventus 2.75Moderate Buy$13.75101.61% UpsidePPHVanEck Pharmaceutical ETF 2.66Moderate Buy$87.80N/ACurrent Analyst Ratings BreakdownLatest PRSM, BVS, PPH, ISX, and IHP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/7/2025BVSBioventusCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$12.005/7/2025BVSBioventusCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$15.00(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBVSBioventus$567.70M0.99$0.54 per share12.58$2.80 per share2.44PPHVanEck Pharmaceutical ETFN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBVSBioventus-$156.23M-$0.48N/A14.83N/A-7.11%15.61%4.01%N/APPHVanEck Pharmaceutical ETFN/AN/A20.21∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBVSBioventusN/AN/AN/AN/AN/APPHVanEck Pharmaceutical ETF$1.952.22%N/AN/AN/ALatest PRSM, BVS, PPH, ISX, and IHP DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date6/30/2025PPHVanEck Pharmaceutical ETFQuarterly$0.60692.75%7/1/20257/1/20257/7/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBVSBioventus1.851.410.99PPHVanEck Pharmaceutical ETFN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBVSBioventus62.94%PPHVanEck Pharmaceutical ETFN/AInsider OwnershipCompanyInsider OwnershipBVSBioventus33.00%PPHVanEck Pharmaceutical ETFN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBVSBioventus1,20082.14 million54.46 millionNot OptionablePPHVanEck Pharmaceutical ETF147,0006.94 millionN/AOptionablePRSM, BVS, PPH, ISX, and IHP HeadlinesRecent News About These CompaniesVanEck Vectors Pharmaceutical ETF declares quarterly distribution of $0.6069July 1, 2025 | msn.comGlobal pharma stocks down as Trump renews tariff threatJune 17, 2025 | msn.comShould You Invest in the VanEck Pharmaceutical ETF (PPH)?May 21, 2025 | zacks.comPPH, Big Pharma Stocks Volatile on Trump Drug PricingMay 14, 2025 | finance.yahoo.comETFs on the Move Post U.S.-China Trade DealMay 12, 2025 | zacks.comA Look at Pharma ETFs After Strong Q1 EarningsMay 8, 2025 | zacks.comPPH: Will Overcome Tariffs, But Competitor Funds Look StrongerApril 14, 2025 | seekingalpha.comBig Pharma higher after tariff exemption despite ongoing uncertaintiesApril 3, 2025 | msn.comShould You Invest in the VanEck Pharmaceutical ETF (PPH)?March 20, 2025 | zacks.comShould You Invest in the VanEck Pharmaceutical ETF (PPH)?January 16, 2025 | zacks.com(PPH) Investment ReportJanuary 6, 2025 | news.stocktradersdaily.comNVanEck Vectors Pharmaceutical ETF declares quarterly distribution of $0.4110December 27, 2024 | msn.comPPH Is a Pertinent Healthcare Idea for 2025December 19, 2024 | etftrends.comE(PPH) Pivots Trading Plans and Risk ControlsDecember 16, 2024 | news.stocktradersdaily.comNWhen the Price of (PPH) Talks, People ListenDecember 6, 2024 | news.stocktradersdaily.comNShould You Invest in the VanEck Pharmaceutical ETF (PPH)?November 11, 2024 | zacks.comThe Zacks Analyst Blog Highlights Eli Lilly, Novo Nordisk, PPH, HRTS and THNROctober 17, 2024 | finance.yahoo.comDiversified Exposure To The Weight Loss Drug MarketOctober 10, 2024 | seekingalpha.comPharma Stocks Losing Ground After A Remarkable Rally, Downgrading PPHOctober 3, 2024 | seekingalpha.comHealthcare ETFs Starting to Look HealthyOctober 1, 2024 | etftrends.comENew MarketBeat Followers Over TimeMedia Sentiment Over TimePRSM, BVS, PPH, ISX, and IHP Company DescriptionsBioventus NYSE:BVS$6.82 -0.20 (-2.85%) As of 04:00 PM EasternBioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain. Its surgical solutions comprise bone graft substitutes that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries; and ultrasonic products used for precise bone cutting and sculpting, soft tissue management, and tissue debridement, in various surgeries, including minimally invasive applications. The company's product include, Osteoamp, an allograft-derived bone graft for bone grafting procedures; Exponent matrix for posterolateral spine procedures; Purebone for bone grafting procedures; Signafuse bone graft; Interfuse bone graft; Osteomatrix+ synthetic bone graft; Extractor for autologous cell and bone marrow extraction; reficio bone matrix; nexus ultrasonic surgical system; bonescalpel surgical solution; SonaStar for surgical procedures; and SonicOne ultrasonic cleansing and debridement system. The company's restorative therapies include a bone stimulation system and devices to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. Its products include exogen, a bone healing system; L300 GO, a foot drop system; H200 rehabilitation system; Vector, a body weight support system; and Bioness integrated therapy system. It developing Talisman pulse generator and receiver for peripheral nerve stimulation. The company was founded in 2011 and is headquartered in Durham, North Carolina.VanEck Pharmaceutical ETF NASDAQ:PPH$87.80 -0.27 (-0.31%) Closing price 04:00 PM EasternExtended Trading$87.58 -0.22 (-0.25%) As of 06:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.The VanEck Pharmaceutical ETF (PPH) is an exchange-traded fund that is based on the MVIS US Listed Pharmaceutical 25 index, a market-cap-weighted index of 25 of the largest global pharmaceutical firms. PPH was launched on Feb 1, 2000 and is managed by VanEck. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Micron Insiders Sell But Investors Should Buy, Buy, Buy Could Dutch Bros Dethrone Starbucks? Why Investors Are Perking Up ExxonMobil: Limited Risk and Lots of Reward With This Oil Play D-Wave Is Rising Again Despite Dilution—What’s the Deal? Datadog Joins S&P 500, Triggering a New Wave of Upside MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
